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Abstract Monogenic diabetes caused by mutations in the
glucokinase gene (GCK-MODY) is usually characterized
by a mild clinical phenotype. The clinical course of dia-
betes may be, however, highly variable. The authors
present a child with diabetes manifesting with ketoacidosis
during the neonatal period, born in a large family with ten
members bearing a heterozygous p.Gly223Ser mutation in
GCK. DNA sequencing and multiplex ligation-dependent
probe ampliﬁcation were used to conﬁrm GCK mutation
and exclude other de novo mutations in other known genes
associated with monogenic diabetes. Continuous glucose
monitoring (CGM) was used to assess daily glycemic
proﬁles. At the onset of diabetes the child had hypergly-
cemia 765 mg/dl with pH 7.09. Her glycated hemoglobin
level was 8.6% (70.5 mmol/mol). The C-peptide level was
below normal range (\0.5 pmol/ml) at onset, and the three-
and 6-month follow-up examinations. Current evaluation at
age 3 still showed unsatisfactory metabolic control with
HbA1c level equal to 8.1% (65.0 mmol/mol). CGM data
showed glucose concentrations proﬁle similar to poorly
controlled type 1 diabetes. The patient was conﬁrmed to
be heterozygous for the p.Gly223Ser mutation and did
not show any point mutations or deletions within other
monogenic diabetes genes. Other family members with
p.Gly223Ser mutation had retained C-peptide levels and
mild diabetes manageable with diet (ﬁve individuals), oral
hypoglycemizing agents (ﬁve patients), or insulin (one
patient). This mutation was absent within all healthy family
members. Heterozygous mutations of the GCK gene may
result in neonatal diabetes similar to type 1 diabetes, the
cause of such phenotype variety is still unknown. The
possibility of other additional, unknown mutations seems
to be the most likely explanation for the unusual presen-
tation of GCK-MODY.
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Introduction
Glucokinase (GCK) plays a crucial role in regulation and
integration of glucose metabolism in beta cells and hepa-
tocytes. Enzymatic activity of GCK is directly associated
with insulin secretion which results in glucokinase acting
as the main glucosensor for the beta cells [1–3].
Heterozygous GCK mutations result in diabetes fol-
lowing a dominant mode of inheritance (GCK-MODY)
which in some cases may be misdiagnosed as idiopathic
type 1 diabetes [4]. The clinical picture usually encom-
passes moderately elevated fasting hyperglycemia with
mildly increased glycated hemoglobin levels. Ketoacidosis
in patients with GCK-MODY is rarely observed, as are
chronic complications of diabetes [5, 6].
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biallelic (homozygous or compound heterozygous) muta-
tions of the GCK gene is dramatically different, e.g., dia-
betes that develop during the initial days of life is difﬁcult
to control and generally unresponsive to treatment other
than with insulin. Such a defect is detected in 5–10% of
patients with persistent neonatal diabetes (PND) [7, 8].
Symptoms of PND with biallelic GCK mutations manifest
during the initial days of life, with pronounced hypergly-
cemia, ketoacidosis, and severe clinical condition [9, 10].
Insulin-based treatment is ubiquitous, but achievement of
optimal metabolic control may be difﬁcult possibly due to
the mixed pancreato-hepatic origin of the disorder. This
report presents a large GCK-MODY family with broad
spectrum of clinical diabetic phenotype among affected
family members.
Materials and methods
The study was conducted in accordance with the Declara-
tion of Helsinki as revised in 2000 and accepted by the
Institutional Bioethics Committee. Participants expressed
their informed consent for participation in the study.
The authors sought to evaluate the clinical and genetic
characteristics of a large family with GCK-MODY with
one individual manifesting severe symptoms of diabetes
during the neonatal period. For further evaluation, the
patient, her sister, and two additional family members with
diabetes were subjected to continuous glucose monitoring
(CGM) examination, by means of Medtronic Diabetes
CGMS (Medtronic, Northridge, CA, USA). Registered data
from the CGMS Digital Recorder and the blood glucose
meter were downloaded and analyzed with the appropriate
dedicated software.
Genetic analysis
DNA was extracted from peripheral blood cells drawn into
EDTA-coated vials. Isolation was performed according to
the manufacturer’s protocol using QiaAmp DNA mini kits
from Qiagen (Qiagen, Hilden, Germany). PCR ampliﬁca-
tion and DNA puriﬁcation were carried out using standard
methods [11, 12]. DNA sequencing was performed using
BigDye Seq kit v3.1 (Applied Biosystems, Foster City, CA,
USA) and pairs of speciﬁc oligonucleotide primers span-
ning the coding and promoter sequence of the GCK gene.
Identiﬁcation of mutations was performed by direct
sequencing using the ABI 3130 genetic analyzer and DNA
Sequencing Analysis Software (Applied Biosystems,
Foster City, CA, USA). For the comparative analysis of
evaluated sequences, human genome reference using
Sequencher software v4.1.4 (GeneCodes, Ann Arbor, MI,
USA) was used. DNA was also subjected to multiplex
ligation-dependent probe ampliﬁcation (MLPA) testing
according to the manufacturer’s protocol using a com-
mercially available set MODY-P241 (MRC-Holland,
Netherlands) to search for deletions in known monogenic
diabetes genes including GCK. The same approach was
implemented for mutation detection in coding and pro-
moter regions (approximately 1,000 bp upstream from
the ﬁrst exon) of HNF1A, HNF4A, PDX1, HNF1B, NEU-
ROD1, KCNJ11, ABCC8, and INS gene in the patient
with onset of diabetes during the neonatal period. All
genetic analysis was performed in the Immunopathology
and Genetics Laboratory at the Department of Pediatrics,
Oncology, Hematology, and Diabetology in Lodz, which
is reference ISO9001 certiﬁed laboratory with Euro-
pean Molecular Genetics Quality Network (EMQN)
collaboration.
Statistical analysis
Continuous variables were presented as medians and
25–75% or as means with standard deviation depending on
distribution. Normalization was performed against region-
speciﬁc means and standard deviation with values pre-
sented as standard deviation scores (SDS). Comparisons of
continuous variables between two groups were made using
the Mann–Whitney’s U test. Statistical signiﬁcance was
declared when a P value 0.05 was observed. Statistica 8.0
(Statsoft, Tulsa, OK, USA) statistical software was used to
perform these analyses.
Subjects studied
Based on the above criteria, the authors found one child
positive for a heterozygous GCK mutation who was dia-
gnosed with PND (denoted as No5109 in the Nationwide
Registry of Monogenic Diabetes). The patient, a female
infant, presented with severe hyperglycemia (765 mg/dl),
dehydration, glucosuria, and ketoacidosis (pH 7.09, BE
14 mM) on the day after her birth. The child was delivered
by natural means from a second, uneventful pregnancy
during the 36th week of gestation. Her birth weight equaled
1,760 g (\2 SDS), body length—46.3 cm (SDS -1.73),
head circumference—30 cm (SDS -2.23), thorax circum-
ference—26 cm (SDS -3.17), Apgar score equaled 7 on
the ﬁrst and 9 on the third minute of life.
For the ﬁrst 72-h after diagnosis, she was treated with
intravenous insulin (dose range: 0.1–0.3 units/kg/h) due to
persistent hyperglycemia (mean value from that period
equaled 340 mg/dl). On the 4th day of life, the girl was
transferred from the Neonatal Care Unit to the Diabetes
Unit. Subsequently, she was given insulin in multiple daily
injections (mean daily dose equaled 0.9 U/kg). In the 7th
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123week of life, continuous subcutaneous insulin infusion
(CSII) therapy using a personal insulin pump was started.
The insulin dose was reduced to 0.4 units/kg per day, and
the blood glucose levels gradually normalized.
Follow-up visits after three and 6 months of treatment
showed that fasting and glucagon stimulated C-peptide
level was\0.5 ng/ml and HbA1c levels 6.5% (47.5 mmol/
mol) and 8.3% (67.2 mmol/mol), respectively. No islet
cell, anti-GAD65, anti-insulinoma-associated antigen-2,
and anti-insulin autoantibodies were detected. At the age
of 6 months, the girl weighted 6,400 g (SDS -1.37) and
achieved all the psychomotor milestones adequate for that
age.
Currently, at the age of 3 years, the child remains
treated with CSII. Her daily insulin dose ranges between
0.6 and 0.8 units/kg per day, but metabolic control of
diabetes is still not satisfactory (median HbA1c level
equaled 8.1% (65.0 mmol/mol)), whereas psychomotor
development was adequate for her age.
DNA sequencing revealed that the proband had hetero-
zygous missense mutation C.667G[A in the GCK gene,
which resulted in the amino acid substitution of glycine to
serine at the 223rd position (p.Gly223Ser) (Fig. 1). Severe
diabetespresentation,whichisunusualamongthecarriersof
heterozygous GCK mutation, suggested a possible biallelic
genetic background (compound heterozygous or homozy-
gous). Since only one heterozygous mutation in GCK locus
was found, the authors decided to perform genetic screening
for mutation in other known monogenic diabetes genes
using both DNA sequencing (for point mutation detection)
and MLPA techniques (for deletions/ampliﬁcations). These
analyses did not reveal any other potentially causative
lesions except the original one—the p.Gly223Ser in GCK.
Mother of the presented patient (aged 21) was diagnosed
with gestational diabetes mellitus that persisted after deliv-
ery. At the moment of evaluation, the state of her diabetes
remained well controlled (HbA1c 5.8% (39.9 mmol/mol))
and she was able to maintain near-normoglycemic levels
using diet only. Her fasting C-peptide level was well within
the normal range (1.42 pmol/ml) and suggested retained
beta cell function. Her siblings: one sister and one brother
have been diagnosed initially with type 1 diabetes mellitus,
which upon later veriﬁcation turned out to be GCK-MODY.
In depth evaluation of the presented family revealed that
eleven out of 27 available family members had diabetes or
impaired glucose tolerance (IGT). This observation gave
strong evidence toward a dominant mode of inheritance.
Complete pedigree analysis of the described family and
Fig. 1 a DNA sequencing results conﬁrming the p.Gly223Ser
mutation in a healthy family member (top chromatogram) and patient
No5109 (bottom chromatogram); b full pedigree of the presented
GCK-MODY family. Patient No5109—marked with an arrow—was
diagnosed with neonatal diabetes. All patients marked as affected had
diabetes or impaired fasting glucose and were heterozygous with the
same p.Gly223Ser mutation located in the exon 6 of the GCK. N wild
type, M p.Gly223Ser mutation
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AnalysisofGCKgeneshowedthatallsubjectswithdiabetes
(n = 9) or IGT (n = 2) were heterozygous carriers of the
p.Gly223Ser substitution, and this mutation was absent in
healthy family members. Interestingly, all affected family
members but patient No5109, had mild clinical presentation
of the disease, retained C-peptide levels, and in all cases but
one did not require insulin treatment (Table 1). The CGM
examination performed in patient No5109 showed 24-h
glucose variability that was markedly different from typical
GCK-MODY and similar to that observed among patients
with type 1 diabetes (Fig. 2 a–c).
Discussion
The majority of patients with heterozygous mutations of
the glucokinase gene (GCK-MODY) may be diagnosed
on clinical features. Symptoms of this form of diabetes
are usually: fasting hyperglycemia [100 mg/dl, HbA1c
levels elevated above normal limit but rarely exceeding
7.5% (58.5 mmol/mol), and small incremental rise of
glycemia in oral glucose tolerance test [13]. The diagnosis
is most often stated during the initial two decades of life
[14]. The p.Gly223Ser mutation known to cause GCK-
MODY in the proband’s family segregated with disease
status in all individuals of the family, and thus a diagnosis
of GCK-MODY was conﬁrmed in 12 out of 27 individ-
uals. The p.Gly223Ser mutation is a known defect of
GCK leading to the development of typical MODY
diabetes, which affects glucokinase activity in functional
studies [15–17].
The observed low fasting C-peptide level—a trait gen-
erally attributed to homozygous GCK mutations [9, 10]—
was the main feature conﬁrming severe beta cell insufﬁ-
ciency in the presented individual. In her family, however,
the level of C-peptide did not differ signiﬁcantly upon the
dependency of mutation carriage. This observation sug-
gested the potential for an additional de novo mutation or a
strong modulating effect of other genetic factors being
active in the proband with neonatal diabetes.
GCK-MODY may be diagnosed in the neonatal period,
but the clinical phenotype is most often mild with fasting
plasma glucose within 6.0–7.6 mmol/l range [18, 19].
Thus, the authors were surprised to observe neonatal dia-
betes with such acute onset as mentioned earlier. Reports
showed signs of ketoacidosis and signiﬁcant hyperglyce-
mia at onset to be extremely rare. Identiﬁcation of a het-
erozygous mutation in GCK during the neonatal period is
still a rare occurrence and, as was the case in the presented
individual, may be a direct consequence of known GCK-
MODY familial background, which guides the physician to
proper diagnosis and rapid deployment of genetic diag-
nostics methods. A similar phenotype occurring in a non-
familial setting would most likely result primarily in
sequencing of KCNJ11, ABCC8, and INS genes as the most
common causes of non-consanguineous cases of neonatal
diabetes [20]. The relatively severe clinical course of dia-
betes with ketoacidosis and low birth weight suggested that
the disease might have been actually caused by an
Table 1 Clinical characteristics of the presented family
Characteristic Patient No5109 Other family members
with diabetes or IGT
Healthy family
members
P
n 11 1 1 5 –
% male Female 64% 40% –
Ketoacidosis at diagnosis pH 7.09
BE 14 mM
None NA –
Age at diagnosis (years) 2nd day after birth 17.5 (9.2–20.7) NA –
Fasting glucose at diagnosis (mg/dl) 765 126 (115–132) 90 (79–102) \10
-5
HbA1c at diagnosis (%) (mmol/mol) 8.6
70.5
6.2 (5.5–6.9)
44.3 (36.6–51.9)
NA –
Treatment Insulin Insulin-1
Oral agents-5
Diet-5
NA –
Median HbAc (%) 8.1 (7.2–8.4)
65 (55.2–68.3)
6.1 (5.5–6.4)
43.2 (36.6–46.5)
5.4 (5.1–5.6)
35.5 (32.2–37.7)
0.002
Fasting C-peptide (pmol/ml) \0.5 1.17 (0.7–1.5) 1.01 (0.5–1.4) 0.53
P values are given for comparisons between the healthy family members and the p.Gly223Ser mutation carriers. Data are presented as medians
with interquartile ranges unless noted otherwise
NA not applicable, IGT impaired glucose tolerance
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123additional de novo mutation in one of those genes exac-
erbating the effect of GCK mutations.
Coexistence of mutations in two separate genes causa-
tive of monogenic diabetes has been reported in several
reports and different combinations. Cervin et al. [21]
described the coexistence of HNF1A mutation with mito-
chondrial diabetes. Coexistence of KCNJ11 with GCK
mutations has been described among Italian patients with
monogenic diabetes [22]. Combinations of HNF1A and
HNF4A mutations were also reported in patients with
monogenic diabetes [23, 24]. A report by Odem et al. [25]
suggested that coexistence of benign mutations in GCK and
PDX1 could potentially lead to diabetes due to the joint
effect of both defects, although this conclusion was not
supported by any functional studies. Attempts to detect
coexisting mutations in other MODY genes were therefore
made, but no mutations were found in any of known
MODY or PND genes. Similarly, no clinical features
suggesting the presence of defects in genes associated with
syndromic diabetes were found. Nevertheless, the
possibility that patient No5109 had a de novo mutation in a
yet undiscovered gene resulting in monogenic diabetes in
addition to the p.Gly223Ser mutation of GCK remains the
most likely explanation of the described phenotype dis-
crepancy. This will necessitate reevaluation as new genes
responsible for this disease are discovered and deﬁned
similarly to other patients with PND of unknown etiology.
The matter of increased ‘‘diabetes awareness’’ of the
mother could contribute toward earlier diagnosis of dia-
betes in her second child if hyperglycemia was the only
symptom at presentation, but cannot possibly explain the
acute onset of symptoms. Finally, a plausible explanation
for the observed phenotype is a modulating effect of
common polymorphisms increasing the risk for developing
diabetes. Potential candidates could include polymor-
phisms or mutations in genes participating in determining
insulin secretion, insulin resistance, or beta cell apoptosis
[26–30]. However, as the question which loci would be
the most likely to exert such effect is unresolved, this
hypothesis is purely speculative.
Fig. 2 Continuous glucose monitoring results of patient No5109 with
a phenotype of neonatal diabetes and heterozygous p.Gly223Ser
mutation in glucokinase (a), her sister with mild phenotype and the
same heterozygous p.Gly223Ser mutation (b) and a 3-year-old patient
with type 1 diabetes mellitus (c)
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123In conclusion, a heterozygous GCK mutation is a factor
leading to monogenic diabetes with very discrepant pheno-
types of the disease. Even within a single family the clinical
presentation may range from severe diabetes manifesting in
infancy to mild hyperglycemia detected accidentally during
later stages of life. The possibility of additional, unknown
genetic defects also seems to be the most likely explanation
for the above-stated unusual presentation of GCK-MODY.
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